Literature DB >> 20939105

Hepatic steatosis, low-grade chronic inflammation and hormone/growth factor/adipokine imbalance.

Giovanni Tarantino1, Silvia Savastano, Annamaria Colao.   

Abstract

Non-alcoholic fatty liver disease (NAFLD), a further expression of metabolic syndrome, strictly linked to obesity and diabetes mellitus, is characterized by insulin resistance (IR), elevated serum levels of free fatty acids and fatty infiltration of the liver, which is known as hepatic steatosis. Hepatocyte apoptosis is a key feature of this disease and correlates with its severity. Free-fatty-acid-induced toxicity represents one of mechanisms for the pathogenesis of NAFLD and hormones, growth factors and adipokines influence also play a key role. This review highlights the various pathways that contribute to the development of hepatic steatosis. Circulating concentrations of inflammatory cytokines are reckoned to be the most important factor in causing and maintaining IR. Low-grade chronic inflammation is fundamental in the progression of NAFLD toward higher risk cirrhotic states.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20939105      PMCID: PMC2955246          DOI: 10.3748/wjg.v16.i38.4773

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  118 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Insulin resistance and cardiovascular disease.

Authors:  H N Ginsberg
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  Leptin resistance is associated with hypothalamic leptin receptor mRNA and protein downregulation.

Authors:  R L Martin; E Perez; Y J He; R Dawson; W J Millard
Journal:  Metabolism       Date:  2000-11       Impact factor: 8.694

4.  Is adiponectin involved in the pathogenesis of nonalcoholic steatohepatitis? A preliminary human study.

Authors:  Raj Vuppalanchi; Smitha Marri; Dhanashri Kolwankar; Robert V Considine; Naga Chalasani
Journal:  J Clin Gastroenterol       Date:  2005-03       Impact factor: 3.062

Review 5.  The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity.

Authors:  E W Kraegen; G J Cooney; J M Ye; A L Thompson; S M Furler
Journal:  Exp Clin Endocrinol Diabetes       Date:  2001       Impact factor: 2.949

6.  Cardiovascular morbidity and mortality associated with the metabolic syndrome.

Authors:  B Isomaa; P Almgren; T Tuomi; B Forsén; K Lahti; M Nissén; M R Taskinen; L Groop
Journal:  Diabetes Care       Date:  2001-04       Impact factor: 19.112

7.  Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin.

Authors:  K Rebrin; G M Steil; L Getty; R N Bergman
Journal:  Diabetes       Date:  1995-09       Impact factor: 9.461

8.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

9.  Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study.

Authors:  H B Hubert; M Feinleib; P M McNamara; W P Castelli
Journal:  Circulation       Date:  1983-05       Impact factor: 29.690

10.  Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism.

Authors:  Yong Fan; Ram K Menon; Pinchas Cohen; David Hwang; Thomas Clemens; Douglas J DiGirolamo; John J Kopchick; Derek Le Roith; Massimo Trucco; Mark A Sperling
Journal:  J Biol Chem       Date:  2009-05-21       Impact factor: 5.157

View more
  74 in total

Review 1.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

2.  Serum adipokines might predict liver histology findings in non-alcoholic fatty liver disease.

Authors:  Raika Jamali; Mohsen Razavizade; Abbas Arj; Mohammad Hossein Aarabi
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

Review 3.  The role of the gut microbiota in NAFLD.

Authors:  Christopher Leung; Leni Rivera; John B Furness; Peter W Angus
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-06-08       Impact factor: 46.802

Review 4.  What is the role of adiponectin in obesity related non-alcoholic fatty liver disease?

Authors:  Carmine Finelli; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 5.  Insulin and bone: Recent developments.

Authors:  Gordon L Klein
Journal:  World J Diabetes       Date:  2014-02-15

Review 6.  Targeting inflammation in diabetes: Newer therapeutic options.

Authors:  Neeraj Kumar Agrawal; Saket Kant
Journal:  World J Diabetes       Date:  2014-10-15

Review 7.  Role of cytokines and chemokines in non-alcoholic fatty liver disease.

Authors:  Vincent Braunersreuther; Giorgio Luciano Viviani; François Mach; Fabrizio Montecucco
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

8.  IGF-1 Levels are Inversely Associated With Metabolic Syndrome in Obstructive Sleep Apnea.

Authors:  Suelem Izumi; Fernando F Ribeiro-Filho; Gláucia Carneiro; Sônia M Togeiro; Sérgio Tufik; Maria T Zanella
Journal:  J Clin Sleep Med       Date:  2016-04-15       Impact factor: 4.062

9.  Increased international normalized ratio level in hepatocellular carcinoma patients with diabetes mellitus.

Authors:  Hui Zhang; Chun Gao; Long Fang; Shu-Kun Yao
Journal:  World J Gastroenterol       Date:  2013-04-21       Impact factor: 5.742

Review 10.  Pathogenesis of liver cirrhosis.

Authors:  Wen-Ce Zhou; Quan-Bao Zhang; Liang Qiao
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.